- Author: Stephanie Danielle Mathew, DO; Chief Editor: Herbert S Diamond, MD more...
Dupuytren disease is a fibrosing disorder that results in slowly progressive thickening and shorting of the palmar fascia and leads to debilitating digital contractures, particularly of the metacarpophalangeal (MCP) joints or the proximal interphalangeal (PIP) joints. This condition usually affects the fourth and fifth digits (the ring and small fingers). See the images below.
Dupuytren contracture belongs to the group of fibromatoses that include plantar fibromatosis (Ledderhose disease), penile fibromatosis (Peyronie disease), and fibromatosis of the dorsal PIP joints (Garrod nodes or knuckle pads). Although many cases appear to be idiopathic, various associated diseases have been reported. See Pathogenesis/Etiology.
Dupuytren contracture is most commonly observed in persons of Northern European descent and affects 4-6% of Caucasians worldwide. Many individuals have bilateral disease (45%); in unilateral cases, the right side is more often affected. The ring finger is most commonly involved, followed by the fifth digit and then the middle finger. The index finger and the thumb are typically spared. See Epidemiology and Presentation.
Although the cause of Dupuytren disease is unknown, a family history is often present. Males are three times as likely to develop disease and are more likely to have higher disease severity.[4, 5] Male predominance may be related to expression of androgen receptors in Dupuytren fascia. See Etiology and Epidemiology.
Other potential risk factors include manual labor with vibration exposure, prior hand trauma, alcoholism, smoking, diabetes mellitus, hyperlipidemia, Peyronie disease, and complex regional pain syndrome. Rheumatoid arthritis seems to protect against the development of Dupuytren disease. See Etiology.
Therapies include conservative medical and surgical modalities. Although the condition is not fatal, significant morbidity can occur if patients are untreated. See Treatment.
Stages of Dupuytren disease
Dupuytren disease occurs in the following three stages:
Proliferative phase - During this phase, myofibroblasts proliferate and a nodule develops. In early disease, some patients may report tenderness and discomfort associated with the nodules. The associated pain is thought to be due to nerve fibers embedded in the fibrous tissue or compression of local nerves.  On physical examination, palmar skin blanching is seen with finger extension.
Involutional phase - In this phase the disease, spreads along the fascia and into the fingers resulting in the development of a cord. Myofibroblasts are the predominant cell type during this phase and align themselves along tension lines within the nodule
Residual phase – During the residual phase, the disease continues to spread into the fingers and the cord tightens creating a contracture. The nodular tissue disappears as do the myofibroblasts and acellular tissue with thick bands of collagen remain.
Grades of severity
The grading system for Dupuytren disease severity is as follows (see the images below) :
Grade 1 - Thickened nodule and band in the palmar aponeurosis; may have associated skin abnormalities
Grade 2 - Development of pretendinous and digital cords with limitation of finger extension
Grade 3 - Presence of flexion contracture
See the images below.
In the normal hand, the palmar aponeurosis runs longitudinally from the wrist, crosses over the superficial transverse palmar ligament, and splits into pretendinous bands to each digit. See the image below.
In the distal palm and fingers, the following superficial fascial components are typically involved in Dupuytren disease:
Lateral digital sheet
The extension of a palmar fascial band to the index finger frequently ends in the skin on the radial side of the hand. The band to the thumb is inconsistent. The insertion of the pretendinous bands to the skin distal to the distal palmar crease is by means of a bifurcate insertion into the side of the finger dorsal to the neurovascular bundle. A natatory ligament runs transversely across each web space distal to the MCP joint, giving fibers that blend with each lateral digital sheet and to the superficial aspect of the flexor tendon sheath. The superficial transverse ligament lies deep to the pretendinous bands, proximal to the MCP joints and the natatory ligament. In the fingers, the Cleland ligament, Landsmeer ligaments (oblique retinacular ligaments), and other deeper fascial layers are usually spared in Dupuytren disease.[10, 11, 12]
According to Luck, normal longitudinal components of the superficial palmar aponeurosis are referred to as bands; diseased tissue is referred to as cords. Cardinal features of Dupuytren disease are the nodule, the cord, and the digital flexion contracture. The bands and cords are characterized as follows:
The pretendinous cord is formed from pretendinous bands.
The spiral cord is made up of the pretendinous band, spiral band, lateral digital sheet, and Grayson ligament; this often occurs in the ring and small fingers and winds around the neurovascular bundle.
The lateral cord is formed from the lateral digital band and is rarely observed, except on the ulnar aspect of the small finger.
The central cord has no defined fascial precursor; it is the most common cause of proximal PIP contracture.
The natatory cord contributes to web space contractures and passes superficial to neurovascular bundles.
See the images below.
Spiral and lateral cords displace the neurovascular bundle toward the digital midline, while a central cord may encase the neurovascular bundle and usually is directed toward one side of the finger. The central, lateral, and spiral cords terminate on the tendon sheath of the adjacent middle phalanx. One or more may be found in any individual patient, but they seldom occur on both sides of the same finger. McFarlane describes displacement of the neurovascular bundle superficially and toward the digital midline by a spiral cord, which makes it more vulnerable to injury during surgery. With increasing degrees of flexion contracture, nerve compression and vascular embarrassment may also occur.
In the thumb, 3 fascial structures may be involved: the natatory ligament, the pretendinous band, and the superficial transverse ligament of the palm. Knuckle pads may develop with fibrosis in the dorsal subcutaneous wrinkle ligaments (of McGrouther) dorsally at the PIP joints. These often indicate progressive disease.
Although the underlying etiology for the development of Dupuytren disease is uncertain, the basic pathophysiology involves fibroblast proliferation, and collagen deposition leading to contractures of the palmar fascia. Investigators have proposed several hypotheses for the pathogenesis of Dupuytren disease. Al-Qattan hypothesizes that an individual with a genetic predisposition to develop Dupuytren disease experiences a second inciting event (ie, smoking, diabetes, trauma, alcoholism), resulting in microvascular ischemia. The localized ischemia causes two events to take place in the palmar fascia: (1) the conversion of adenosine triphosphate to hypoxanthine and (2) the conversion of xanthine dehydrogenase to xanthine oxidase.
Xanthine oxidase acts as a catalyst for the oxidation of hypoxanthine to xanthine and uric acid; this conversion results in the production of free radicals. Free radicals result in fibroblast proliferation and the production of numerous cytokines. Interleukin 1 (IL-1) is the most abundant cytokine in Dupuytren disease and, via its receptor, upregulates the production of transforming growth factor beta (TGF-beta), fibroblast growth factor, epidermal-derived growth factor, and platelet-derived growth factor.[14, 15] This milieu of cytokines and growth factors results in the proliferation of fibroblasts and their differentiation into myofibroblasts (the primary cell type in Dupuytren disease).
Increased levels of nerve growth factor are present, which induce fibroblast transformation to myofibroblasts, especially during stages II-III. The splicing of fibronectin affects collagen binding. Platelet activation produces lysophosphatidic acid (LPA). LPA is a signaling molecule for cell proliferation and myofibroblast contraction. After binding to its receptor on myofibroblasts, LPA leads to a decrease in cyclic adenosine monophosphate and an increase in intracellular calcium levels. These events mediate smooth muscle contraction of the myofibrils within the myofibroblast. Normal palmar fascia is primarily composed of type I collagen; Dupuytren disease is associated with an increase in type III collagen.
The ratio of type III collagen to type I collagen increases, the reverse of the normal pattern, in the palmar fascia. Excess type III collagen production occurs from an increased density of fibroblasts secondary to enhanced stimulation and diminished apoptosis, as well as an imbalance between the collagenases and their endogenous inhibitors. Dupuytren fascia exhibits an increased ratio of tissue inhibitors of metalloproteinases (TIMP) to matrix metalloproteinases (MMP).[17, 18, 19]
The myofibroblasts are indirectly connected to collagen, and the contractile force is transmitted from the intracellular actin microfilaments to the collagen bundles. Ultimately, the end result is contracture from excess deposition of type III collagen and the formation of cross-links between myofibroblasts and collagen. Another hypothesis by Vi et al suggests an up regulation of the gene transcript POSTN mRNA that encodes the protein periostin. Periostin is secreted by diseased cord myofibroblasts into the extracellular matrix. It promotes the transition of palmar fascia fibroblasts into a myofibroblast phenotype, thereby enhancing disease progression.
Additionally periostin is prevalent during the early stages of bone fracture repair and vascular injury. Hueston advanced the extrinsic theory, suggesting that Dupuytren’s nodules arise de novo and progress to cords. Vasomotor disturbance and neurovascular mediation by the skin are possible contributors to the development of Dupuytren disease. In contrast, McFarlane postulated the intrinsic theory, that the cords of more advanced Dupuytren disease are derived from normal fascia. A combination of these ideas forms the synthesis theory, which states that the nodules and pretendinous cords represent different forms of the disease.
Furthermore, DNA microarray analysis has demonstrated that the gene MafB is up-regulated in Dupuytren cord tissue. MafB is involved in tissue development and cellular differentiation.[25, 24] Further support for a genetic link was provided by Al-Qattan, who described a maternally transmitted inheritance within the mitochondrial genome in 90% of patients. The defective mitochondria generate high levels of free radicals and defective apoptosis and are therefore directly related to disease pathogenesis.
Another study of 20 patients with apparent maternal inheritance identified a polymorphism in the mitochondrial 16s rRNA region present in 90% of their DNA. Other studies suggest an autosomal dominant pattern of inheritance with variable penetrance. One such study analyzed 5 generations of a Swedish family and mapped the affected gene (not yet identified) to 16q. Some authors suggest an error in growth and regulation of the fibroblast resulting from chromosomal abnormalities, similar to those seen in cells undergoing neoplastic changes. Trisomy 7 and 8 have been identified in the fibroblasts excised from some patients. Nodules may display features of a benign neoplasm.
Others believe that Dupuytren contracture has a multifactorial inheritance, similar to diabetes or hypertension.
Additional risk factors
Whether certain conditions represent independent risk factors for the development of Dupuytren contracture is unclear. A large, retrospective study by Loos and colleagues on 2919 hands on which surgery had been performed revealed no statistically significant evidence that the occurrence of Dupuytren contracture could be correlated with the presence of diabetes, with alcoholism, or with smoking.
Another report, however, found different results, noting an association between Dupuytren contracture and several conditions (eg, alcoholism, diabetes, epilepsy, pulmonary disease), as well as a link with smoking. Nonetheless, even if such associations exist, no clear causal relationship has been established in the literature.
HLA-DRB1*15 and HLA-DR3 have been identified in numerous patients, suggesting an immunologic influence. Each confers about a 2-3 times relative risk for the development of Dupuytren disease.[32, 33] Most likely, an inciting disease or event in a genetically predisposed individual causes a cascade of events that may include processes that promote the formation of growth factors and free radicals that ultimately leads to abnormal fibroproliferation and the appearance of the characteristic Garrod nodule. Even when homeostasis is ultimately achieved and fibroblastic growth lessens, the pathologic nodule and cord remain.
Many hand surgeons believe that trauma to the hand or the distal part of the forearm, such as falling on an outstretched hand, may precipitate the onset. (A positive family history may play a role in occupational and traumatic cases of Dupuytren disease.) However, numerous population-based studies have failed to conclusively link Dupuytren disease to trauma, although case reports have suggested a possible association. Reports by Lucas et al found increased Dupuytren disease in a group of French male civil servants with occupational exposure to vibration and manual work.
Case reports of Dupuytren disease occurring after surgical injury to the hand have been identified, with the authors suggesting that injury can trigger the onset of Dupuytren disease. A history of manual labor with vibration exposure or recurrent trauma has been found to result in a 5-fold increase in the incidence of Dupuytren disease.[37, 38, 39] Liss performed a systemic review of the literature regarding occupation and Dupuytren disease. Although he failed to identify a link between trauma and development of disease, he did find an association between occupational exposure to vibration and Dupuytren disease.
Notably, the exposure in one study was severe enough to cause persistent symptomatic circulatory disturbance ("vibration white finger") ; in another, the exposure was associated with other soft tissue "wasting" and peripheral nerve damage. In a review of 46 available studies, Melhom and Ackerman concluded evidence suggests an association between Dupuytren disease and vibration but not with highly repetitive or forceful work.
Diabetes mellitus has been identified as a risk factor. Dupuytren disease in patients with diabetes ranges from 1.6-32%, the prevalence of diabetes in patients with Dupuytren disease is 5%. The use of insulin and oral hypoglycemics are strongly associated with Dupuytren disease. The disease seems to occur at a younger age and tends to be more severe in those with type 1 diabetes.
Patients with diabetes mellitus and Dupuytren disease have a 4-fold increased risk of developing microalbuminuria than do persons with diabetes alone. A higher incidence of retinopathy was identified in diabetics with Dupuytren contracture, likely attributable to microangiopathic changes. Alcoholic liver disease Individuals with alcohol-related liver disease have an increased prevalence of Dupuytren contracture (approximately 20%) compared with control populations. Patients with liver disease from other causes do not appear to be at increased risk. The reason for this is unknown, and some studies have disputed the association.
A 3-fold increased risk for Dupuytren contracture is seen in individuals who smoke, even when studies control for alcohol use, perhaps due to microvascular impairment. Autoantibodies to connective tissue Significant associations have been found with HLA-DRB1*15, HLA-DR3 and autoantibodies to collagen types I-IV have been reported.
Two studies have shown increased sensitivity to androgens in the palmar fascia.[46, 47] This may account for the male predominance of the disease.
Although implicated in previous studies, little conclusive evidence has been reported to link epilepsy and antiepileptic medications to the development of Dupuytren contracture. Phenobarbitone, in particular, results in increased LPA levels. Although the incidence of Dupuytren disease is 2-3 times higher in individuals with epilepsy, opinions about the cause differ. One group of investigators concluded that electroencephalogram (EEG) abnormalities were more common in patients with Dupuytren disease than in persons with other clinical conditions.
Another study showed a correlation between increased barbiturate medication and a higher occurrence of Dupuytren disease, whereas other studies implicated a genetic link between the two diseases.
Results are conflicting as to whether the human immunodeficiency virus (HIV) is implicated in some cases of Dupuytren disease. Bower et al demonstrated an increased incidence in patients with both Dupuytren contracture and HIV infection, whereas a study by French et al showed no statistically significant difference in these patients compared with the general population.
Dupuytren disease is common in the United States with a prevalence of 4%, reflecting immigration from Northern Europe. In Northern Europe the prevalence ranges from 4-39%. In Norwegian populations, 30% of males over the age of 60 years are affected. The incidence of Dupuytren disease for the British population in 2004 was calculated at 34.4 per 100,000 for men aged 40-84 years. Australia has a reported prevalence of 28%; Spain's reported prevalence is 19% prevalence in in men older than 60 years. Sporadic cases are reported in Africa and Asia.
The effects of morbidity in Dupuytren contracture are generally limited to lifestyle changes. MCP and PIP joint contractures may interfere with activities of daily living and the nodules can be painful. Occasionally, Dupuytren contracture is associated with plantar fascial thickening (Ledderhose disease), involvement of the penis (Peyronie disease), or involvement of the knuckle pads (Garrod nodes). These associations tend to reflect more aggressive disease. No mortality occurs from Dupuytren contracture.
Racial variation in Dupuytren disease is as follows:
Dupuytren disease is most often found in Caucasians of Northern European descent.
The disease prevalence in Asians is 3% and usually involves the palm rather than the digits. Therefore, it is less likely to be clinically significant, and the incidence may be underreported.
Dupuytren disease has been reported in East Africa, Zimbabwe, and Tanzania. 
Dupuytren disease is uncommon among Indians (< 1%), Native Americans, and patients of Hispanic descent. 
Approximately 80% of affected individuals are male; this is consistent throughout all countries and races. The disease onset in males tends to occur in the fifth to sixth decade. Men tend to present a decade earlier than females. The disease course tends to be more rapid and severe in males and increases in incidence with advancing age.
Patients must have realistic expectations that surgery can relieve some disability but that it cannot cure Dupuytren disease. Discuss all potential complications of the procedure, including complex regional pain syndrome. In addition, intensive rehabilitation with an occupational therapist is necessary postoperatively for an optimal outcome.
Verheyden CN. The history of Dupuytren's contracture. Clin Plast Surg. 1983 Oct. 10(4):619-25. [Medline].
Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009 Sep 3. 361(10):968-79. [Medline].
Wheeless Clifford. Wheeless' Textbook of Orthopedics: Dupuytren's Contracture. Ortho Preferred. Available at http://wheelessonline.com/ortho/dupuytrens_contracture. Accessed: September 22 2010.
Geoghegan JM, Forbes J, Clark DI, Smith C, Hubbard R. Dupuytren's Disease Risk Factors. J Hand Surg. 2004/10. 29B:423-426. [Medline].
Al-Qattan MM. Factors in the pathogenesis of Dupuytren's contracture. J Hand Surg Am. 2006 Nov. 31(9):1527-34. [Medline].
Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y). 2009 Sep. 4(3):256-69. [Medline]. [Full Text].
Meathrel KE, Thoma A. Abductor digiti minimi involvement in Dupuytren's contracture of the small finger. J Hand Surg Am. 2004 May. 29(3):510-3. [Medline].
Fitzgerald AM, Kirkpatrick JJ, Naylor IL. Dupuytren's disease. The way forward?. J Hand Surg Br. 1999 Aug. 24(4):395-9. [Medline].
Trojian TH, Chu SM. Dupuytren's disease: diagnosis and treatment. Am Fam Physician. 2007 Jul 1. 76(1):86-9. [Medline].
Strickland JW, Leibovic SJ. Anatomy and pathogenesis of the digital cords and nodules. Hand Clin. 1991 Nov. 7(4):645-57; discussion 659-60. [Medline].
McFarlane RM. The anatomy of Dupuytren's disease. Bull Hosp Jt Dis Orthop Inst. 1984 Fall. 44(2):318-37. [Medline].
Luck JV. Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am. 1959 Jun. 41-A(4):635-64. [Medline].
Kopp J, Seyhan H, Müller B, et al. N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling. J Cell Mol Med. 2006 Jan-Mar. 10(1):157-65. [Medline].
Bansal V, Naidu SH. Dupuytren's disease. Curr Opin Orthop. 2005. 16(4):236-9.
McFarlane RM. Patterns of the diseased fascia in the fingers in Dupuytren's contracture. Displacement of the neurovascular bundle. Plast Reconstr Surg. 1974 Jul. 54(1):31-44. [Medline].
Ulrich D, Ulrich F, Piatkowski A, Pallua N. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Arch Orthop Trauma Surg. 2009 Nov. 129(11):1453-9. [Medline].
Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, Clark IM. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg Am. 2007 Mar. 32(3):343-51. [Medline].
Johnston P, Larson D, Clark IM, Chojnowski AJ. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am. 2008 Sep. 33(7):1160-7. [Medline].
Vi L, Feng L, Zhu RD, Wu Y, Satish L, Gan BS, et al. Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells. Exp Cell Res. 2009 Dec 10. 315(20):3574-86. [Medline].
MacCallum P, Hueston JT. The pathology of Dupuytren's contracture. Aust N Z J Surg. 1962 May. 31:241-53. [Medline].
Gosset J. DDupuytren's disease and the anatomy of the palmodigital aponeurosis. Hueston JT, Tubiana R. Dupuytren's Disease. London: Churchill, Livingstone; 1985. 13-16.
Burge P. Genetics of Dupuytren's disease. Hand Clin. 1999 Feb. 15(1):63-71. [Medline].
Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. J Hand Surg Am. 2006 Feb. 31(2):204-10. [Medline].
Lee LC, Zhang AY, Chong AK, Pham H, Longaker MT, Chang J. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg Am. 2006 Feb. 31(2):211-8. [Medline].
Bayat A, Walter J, Lambe H, et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg. 2005 Jan. 115(1):134-41. [Medline].
von Campe A, Mende K, Omaren H, Meuli-Simmen C. Painful nodules and cords in Dupuytren Disease. J Hand Surg. July 2012. 37a:1315-1318. [Medline].
Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet. 2005 Nov. 68(5):424-9. [Medline].
Dal Cin P, De Smet L, Sciot R, Van Damme B, Van den Berghe H. Trisomy 7 and trisomy 8 in dividing and non-dividing tumor cells in Dupuytren's disease. Cancer Genet Cytogenet. 1999 Jan 15. 108(2):137-40. [Medline].
Loos B, Puschkin V, Horch RE. 50 years experience with Dupuytren's contracture in the Erlangen University Hospital--a retrospective analysis of 2919 operated hands from 1956 to 2006. BMC Musculoskelet Disord. 2007 Jul 4. 8:60. [Medline]. [Full Text].
McCarty S, Farhatullah S, Bayat A. Role of the HLA System in the Pathogenesis of Dupuytren's Disease. Hand. 2010/2. 5:241-250.
Neumuller J, Menzel J, Millesi H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. Clin Immunol Immunopathol. 1994 May. 71(2):142-8. [Medline].
Kelly SA, Burke FD, Elliot D. Injury to the distal radius as a trigger to the onset of Dupuytren's disease. J Hand Surg Br. 1992 Apr. 17(2):225-9. [Medline].
Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med. 1996 May. 29(5):521-32. [Medline].
Lucas G, Brichet A, Roquelaure Y, Leclerc A, Descatha A. Dupuytren's disease: personal factors and occupational exposure. Am J Ind Med. 2008 Jan. 51(1):9-15. [Medline].
Thomas PR, Clarke D. Vibration white finger and Dupuytren's contracture: are they related?. Occup Med (Lond). 1992 Aug. 42(3):155-8. [Medline].
Cocco PL, Frau P, Rapallo M, Casula D. [Occupational exposure to vibration and Dupuytren's disease: a case-controlled study]. Med Lav. 1987 Sep-Oct. 78(5):386-92. [Medline].
Dasgupta AK, Harrison J. Effects of vibration on the hand-arm system of miners in India. Occup Med (Lond). 1996 Feb. 46(1):71-8. [Medline].
Melhom JM, Ackerman III WE. Guides to the Evaluation of Disease and Injury Causation. American Medical Association Press; 2007. 147-152 and 191-202.
Chen LH, Li CY, Kuo LC, Wang LY, Kuo KN, Jou IM, et al. Risk of Hand Syndromes in Patients With Diabetes Mellitus: A Population-Based Cohort Study in Taiwan. Medicine (Baltimore). 2015 Oct. 94 (41):e1575. [Medline].
Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br. 1984 May. 66(3):322-5. [Medline].
Thurston A. Dupuytren's disease or Cooper's contracture?: Kenneth Fitzpatrick Russell Memorial Lecture. ANZ J Surg. 2003 Jul. 73(7):529-35. [Medline].
Gudmundsson KG, Arngrimsson R, Jonsson T. Dupuytren's disease, alcohol consumption and alcoholism. Scand J Prim Health Care. 2001 Sep. 19(3):186-90. [Medline].
Brown JJ, Ollier W, Thomson W, Bayat A. Positive association of HLA-DRB1*15 with Dupuytren's disease in Caucasians. Tissue Antigens. 2008 Aug. 72(2):166-70. [Medline].
Kuhn MA, Wang X, Payne WG, Ko F, Robson MC. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. J Surg Res. 2002 Apr. 103(2):146-52. [Medline].
Pagnotta A, Specchia N, Soccetti A, Manzotti S, Greco F. Responsiveness of Dupuytren's disease fibroblasts to 5 alpha-dihydrotestosterone. J Hand Surg Am. 2003 Nov. 28(6):1029-34. [Medline].
Critchley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren's disease in epilepsy: result of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry. 1976 May. 39(5):498-503. [Medline]. [Full Text].
French PD, Kitchen VS, Harris JR. Prevalence of Dupuytren's contracture in patients infected with HIV. BMJ. 1990 Oct 27. 301 (6758):967. [Medline].
Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren's diathesis revisited: Evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am. 2006 Dec. 31(10):1626-34. [Medline].
Bayat A, Cunliffe EJ, McGrouther DA. Assessment of clinical severity in Dupuytren's disease. Br J Hosp Med (Lond). 2007 Nov. 68(11):604-9. [Medline].
Balaguer T, David S, Ihrai T, Cardot N, Daideri G, Lebreton E. Histological staging and Dupuytren's disease recurrence or extension after surgical treatment: a retrospective study of 124 patients. J Hand Surg Eur Vol. 2009 Aug. 34(4):493-6. [Medline].
Lam WL, Rawlins JM, Karoo RO, Naylor I, Sharpe DT. Re-visiting Luck's classification: a histological analysis of Dupuytren's disease. J Hand Surg Eur Vol. 2010 May. 35(4):312-7. [Medline].
Rayan GM. Nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2008 Sep. 33(7):1208-10. [Medline].
Ketchum LD, Donahue TK. The injection of nodules of Dupuytren's disease with triamcinolone acetonide. J Hand Surg Am. 2000 Nov. 25(6):1157-62. [Medline].
Ketchum LD. The Rationale for Treating the Nodule in Dupuytren's Disease. Plast Reconstr Surg Glob Open. 2014 Dec. 2 (12):e278. [Medline].
Betz N, Ott OJ, Adamietz B, Sauer R, Fietkau R, Keilholz L. Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years. Strahlenther Onkol. 2010 Feb. 186(2):82-90. [Medline].
Collagenase Clostridium Histolyticum [package insert]. Malver, PA: Auxilium Pharmaceuticals. 2010. Available at [Full Text].
Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010. 35:2027-2038. [Medline].
Witthaut J, Jones G, Skrepnik N, Kushner H, Houston A, Lindau TR. Efficacy and safety of collagenase clostridium histolyticum injection for dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am. 2013. 38:2-11. [Medline].
Peimer CA, Blazar P, Coleman S, Kaplan TD, Smith T, Tursi JP, et al. Dupuytren Contracture Recurrence Following Treatment with Clostridium Collagenase Histolyticum (CORDLESS study):3-Year Data. J Hand Surg Am. 2013. 38:12-22. [Medline].
Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014 Jan. 39 (1):57-64. [Medline].
Hand L. FDA expands Dupuytren’s contracture use for Xiaflex. Medscape Medical News. October 21, 2014. [Full Text].
Bulstrode NW, Mudera V, McGrouther DA, Grobbelaar AO, Cambrey AD. 5-fluorouracil selectively inhibits collagen synthesis. Plast Reconstr Surg. 2005 Jul. 116(1):209-21; discussion 222-3. [Medline].
Jemec B, Linge C, Grobbelaar AO, Smith PJ, Sanders R, McGrouther DA. The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation. Chir Main. 2000 Feb. 19(1):15-22. [Medline].
Namazi H. Imiquimod: a potential weapon against Dupuytren contracture. Med Hypotheses. 2006. 66(5):991-2. [Medline].
Namazi H, Abdinejad F. Botulinum Toxin as a novel addition to the antidupuytren armamentarium. Med Hypotheses. 2007. 68(1):240-1. [Medline].
Yildiz S, Karacaoglu E, Pehlivan O. Hyperbaric oxygen for the treatment of early-phase Dupuytren's contracture. Microsurgery. 2004. 24(1):26-9. [Medline].
Mavrogenis AF, Spyridonos SG, Ignatiadis IA, et al. Partial fasciectomy for Dupuytren's contractures. J Surg Orthop Adv. 2009 Summer. 18(2):106-10. [Medline].
Zyluk A, Jagielski W. The effect of the severity of the Dupuytren's contracture on the function of the hand before and after surgery. J Hand Surg Eur Vol. 2007 Jun. 32(3):326-9. [Medline].
Lilly SI, Stern PJ. Simultaneous carpal tunnel release and Dupuytren's fasciectomy. J Hand Surg Am. 2010 May. 35(5):754-9. [Medline].
Zhou C, Hovius SE, Slijper HP, Feitz R, Van Nieuwenhoven CA, Pieters AJ, et al. Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study. Plast Reconstr Surg. 2015 Jul. 136 (1):87-97. [Medline].
van Rijssen AL, Gerbrandy FS, Ter Linden H, Klip H, Werker PM. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: a 6-week follow-up study. J Hand Surg Am. 2006 May-Jun. 31(5):717-25. [Medline].
van Rijssen AL, Werker PM. Percutaneous needle fasciotomy in dupuytren's disease. J Hand Surg Br. 2006 Oct. 31(5):498-501. [Medline].
Cheng HS, Hung LK, Tse WL, Ho PC. Needle aponeurotomy for Dupuytren's contracture. J Orthop Surg (Hong Kong). 2008 Apr. 16(1):88-90. [Medline].
Symes T, Stothard J. Two significant complications following percutaneous needle fasciotomy in a patient on anticoagulants. J Hand Surg Br. 2006 Dec. 31(6):606-7. [Medline].
Denkler K. Options for severe proximal interphalangeal joint contractures in dupuytren contracture. Plast Reconstr Surg. 2012. 130:205e-206e. [Medline].
Foucher G, Medina J, Navarro R. Percutaneous needle aponeurotomy: complications and results. J Hand Surg Br. 2003 Oct. 28(5):427-31. [Medline].
Moermans JP. Long-term results after segmental aponeurectomy for Dupuytren's disease. J Hand Surg Br. 1996 Dec. 21(6):797-800. [Medline].
Moermans JP. Segmental aponeurectomy in Dupuytren's disease. J Hand Surg Br. 1991 Aug. 16(3):243-54. [Medline].
Ali SN, McMurtrie A, Rayatt S, Roberts JO. Ulnar-based skin flap for Dupuytren's fasciectomy. Scand J Plast Reconstr Surg Hand Surg. 2006. 40(5):307-10. [Medline].
Pelissier P, Gardet H, Pinsolle V. The palmar intermetacarpal flap in Dupuytren's contracture. J Hand Surg Eur Vol. 2007 Feb. 32(1):113. [Medline].
Hueston JT. Limited fasciectomy for Dupuytren's contracture. Plast Reconstr Surg Transplant Bull. 1961 Jun. 27:569-85. [Medline].
Högemann A, Wolfhard U, Kendoff D, Board TN, Olivier LC. Results of total aponeurectomy for Dupuytren's contracture in 61 patients: a retrospective clinical study. Arch Orthop Trauma Surg. 2009 Feb. 129(2):195-201. [Medline].
Tripoli M, Merle M. The "Jacobsen Flap" for the treatment of stages III-IV Dupuytren's disease: a review of 98 cases. J Hand Surg Eur Vol. 2008 Dec. 33(6):779-82. [Medline].
Skoff HD. The surgical treatment of Dupuytren's contracture: a synthesis of techniques. Plast Reconstr Surg. 2004 Feb. 113(2):540-4. [Medline].
Ullah AS, Dias JJ, Bhowal B. Does a 'firebreak' full-thickness skin graft prevent recurrence after surgery for Dupuytren's contracture?: a prospective, randomised trial. J Bone Joint Surg Br. 2009 Mar. 91(3):374-8. [Medline].
Villani F, Choughri H, Pelissier P. [Importance of skin graft in preventing recurrence of Dupuytren's contracture]. Chir Main. 2009 Dec. 28(6):349-51. [Medline].
Mullins PA. Postsurgical rehabilitation of Dupuytren's disease. Hand Clin. 1999 Feb. 15(1):167-74, viii. [Medline].
Jerosch-Herold C, Shepstone L, Chojnowski AJ, Larson D. Splinting after contracture release for Dupuytren's contracture (SCoRD): protocol of a pragmatic, multi-centre, randomized controlled trial. BMC Musculoskelet Disord. 2008 Apr 30. 9:62. [Medline]. [Full Text].
Evans RB, Dell PC, Fiolkowski P. A clinical report of the effect of mechanical stress on functional results after fasciectomy for Dupuytren's contracture. J Hand Ther. 2002 Oct-Dec. 15(4):331-9. [Medline].
Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2002 Sep. 27(5):788-98. [Medline].
Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytren's disease. Hand Clin. 1999 Feb. 15(1):97-107, vii. [Medline].
Starkweather KD, Lattuga S, Hurst LC, et al. Collagenase in the treatment of Dupuytren's disease: an in vitro study. J Hand Surg Am. 1996 May. 21(3):490-5. [Medline].
Warren RF. The pathology of Dupuytren's contracture. Br J Plast Surg. 1953 Oct. 6(3):224-30. [Medline].
Hnanicek J, Cimburova M, Putova I, et al. Lack of association of iron metabolism and Dupuytren's disease. J Eur Acad Dermatol Venereol. 2008 Apr. 22(4):476-80. [Medline].
Ross DC. Epidemiology of Dupuytren's disease. Hand Clin. 1999 Feb. 15(1):53-62, vi. [Medline].
Donaldson OW, Pearson D, Reynolds R, Bhatia RK. The association between intraoperative correction of Dupuytren's disease and residual postoperative contracture. J Hand Surg Eur Vol. 2010 Mar. 35(3):220-3. [Medline].
Anwar MU, Al Ghazal SK, Boome RS. Results of surgical treatment of Dupuytren's disease in women: a review of 109 consecutive patients. J Hand Surg Am. 2007 Nov. 32(9):1423-8. [Medline].
Saboeiro AP, Porkorny JJ, Shehadi SI, Virgo KS, Johnson FE. Racial distribution of Dupuytren's disease in Department of Veterans Affairs patients. Plast Reconstr Surg. 2000 Jul. 106(1):71-5. [Medline].
Misra A, Jain A, Ghazanfar R, Johnston T, Nanchahal J. Predicting the outcome of surgery for the proximal interphalangeal joint in Dupuytren's disease. J Hand Surg Am. 2007 Feb. 32(2):240-5. [Medline].
Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren's contracture surgery. J Hand Surg Am. 2005 Sep. 30(5):1021-5. [Medline].
Lanzettá M, Morrison WA. Dupuytren's disease occurring after a surgical injury to the hand. J Hand Surg Br. 1996 Aug. 21(4):481-3. [Medline].
McFarlane RM. On the origin and spread of Dupuytren's disease. J Hand Surg Am. 2002 May. 27(3):385-90. [Medline].
Shih B, Wijeratne D, Armstrong DJ, Lindau T, Day P, Bayat A. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg Am. 2009 Jan. 34(1):124-36. [Medline].
Watt AJ, Curtin CM, Hentz VR. Collagenase injection as nonsurgical treatment of Dupuytren's disease: 8-year follow-up. J Hand Surg Am. 2010 Apr. 35(4):534-9, 539.e1. [Medline].